FDA Clears Investigational New Drug Application for R-5780 in Solid Tumors
The RISE R-5780-01 trial will evaluate the safety and tolerability of R-5780 in patients with melanoma, basal cell carcinoma, or squamous cell carcinoma.
Related Articles
Aspiring Professional Musician Finds Success in Moffitt’s Arts in Medicine Program
Corbin Smith is one of five artists-in-residence at the cancer center
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients…
Welcome! You are invited to join a webinar: AHNS Virtual Education Series: From the Bench to the Bedside: Using Preclinical Models to Advance the Management of Head and Neck Cancer. After registering, you will receive a confirmation email about joining the webinar.
January 22, 2025 Learning Objectives: Define the spectrum of contemporary preclinical models of HNSCC. Describe the strengths and weaknesses of contemporary preclinical models of HNSCC.…
FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer | Cancer Today
Recent findings support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months.
Fox Chase Cancer Center Welcomes Dr. Qing Chen
Qing Chen, MD, PhD, has joined as a new assistant professor in the Cancer Signaling and Microenvironment Research Program.
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Frontline MCL | Blood Cancers Today
In the phase 3 ECHO trial, acalabrutinib with bendamustine and rituximab reduced the risk of disease progression or death by 27% compared with standard-of-care chemoimmunotherapy.
Evaluating a CNS-Penetrant EGFR Inhibitor in Brain Cancer
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Cervical Cancer Screening: Somatic Mutations
Investigators in the Clinical Genetics Branch, led by senior investigator Lisa Mirabello and former research fellow Maísa Pinheiro, used deep targeted sequencing to look for…
